Clinical trials
CAR-T Cell Therapy clinical trials
Below are recruiting car-t cell therapy clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06880913RecruitingPhase 1/Phase 2
Dual CAR-T therapy for relapsed B-cell acute lymphoblastic leukemia
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It's for people whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 12–65 - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17 - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06793241RecruitingEarly Phase 1
Donor CAR-T cells for B-cell leukemia
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Hangzhou, ZhejiangAges 18 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06784726RecruitingPhase 2
Odronextamab before CAR-T for large B-cell lymphoma
This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.
Seattle, WashingtonAges 18 years+ - NCT06787560RecruitingEarly Phase 1
CAR-T cells and stem cell transplant for blood diseases
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Hangzhou, ZhejiangAges Any age - NCT06788964RecruitingPhase 2
Bridge therapy with loncastuximab and rituximab before CAR-T for lymphoma
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
Chapel Hill, North CarolinaAges 18 years+ - NCT06785519RecruitingEarly Phase 1
CAR-T cell therapy for stubborn lupus kidney disease
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06759181RecruitingPhase 1/Phase 2
CAR-T targeting BCMA and FcRL5 for relapsed/refractory myeloma
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
XuzhouAges 18–70 - NCT06752785RecruitingPhase 1
CAR-T cell therapy for children with ALL and minimal residual disease
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Guangzhou, GuangdongAges 1–18 - NCT06732232RecruitingEarly Phase 1
CAR-T therapy for multiple myeloma that returned or didn't respond
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
ShanghaiAges 18–75 - NCT06730256RecruitingEarly Phase 1
Cell therapy for hard-to-treat multiple myeloma and plasma cell leukemia
This study tests a new cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that is not responding to standard treatments or has come back. The therapy uses your own immune cells that are modified to fight the cancer.
Suzhou, JiangsuAges 18 years+ - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06718270RecruitingEarly Phase 1
Study of CT0596 for Relapsed or Refractory Myeloma
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT06706102RecruitingPhase 4
Study of Tiny Blood Particles During CAR-T Therapy
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Saint-EtienneAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car-t cell therapy?
- Yes. Clin2 currently lists 484 recruiting car-t cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car-t cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car-t cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.